"We have four clear areas of focus this year: to file the BLA for afami-cel, continue to build our MAGE-A4 franchise, scale up our manufacturing capabilities, and continue to advance our allogeneic products. We have made good progress with each in 2022," said Adrian Rawcliffe, Adaptimmune's Chief Executive Officer. "We remain funded into early 2024 and will continue to execute across these objectives." Roadmap to BLA submission for afami-cel 1 in 2022 (first-generation product targeting MAGE-A4) Preclinical data at the American Society for Cell and Gene Therapy (ASGCT) annual conference Corporate The Company appointed Dr. Joanna (Jo) Brewer as its Chief Scientific Officer effective May 4; Dr. Brewer previously served as the Company's SVP Allogeneic Research.